• 1
    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
  • 2
    Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, et al. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther 2006; 14: 236-244.
  • 3
    Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001; 75: 8074-8081.
  • 4
    Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002; 55: 107-116.
  • 5
    Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005; 79: 1943-1947.
  • 6
    Khan M, Dhanwani R, Patro IK, Rao PV, Parida MM. Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 2011; 89: 1-8.
  • 7
    Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-1462.
  • 8
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res 2011; 157: 61-70.
  • 9
    Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53: 32-41.
  • 10
    Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177: 705-706.
  • 11
    Pan Q, Tilanus HW, Janssen HL, van der Laan LJ. Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. Hepatology 2011; 53: 1400-1401; author reply 1402.
  • 12
    Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694-703.
  • 13
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
  • 14
    Brandhorst G, Brehmer F, Petrova DT, Gross O, Miosge N, Armstrong VW, et al. Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis. Ther Drug Monit 2010; 32: 73-78.
  • 15
    Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27290.
  • 16
    Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005; 50: 719-726.
  • 17
    Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
  • 18
    Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 2006; 13: 690-700.
  • 19
    Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254.
  • 20
    Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
  • 21
    Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit 2006; 28: 116-122.
  • 22
    Matsuzawa Y, Nakase T. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. J Pharmacobiodyn 1984; 7: 776-783.
  • 23
    Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750-759.
  • 24
    Demirkiran A, Sewgobind VD, van der Weijde J, Kok A, Baan CC, Kwekkeboom J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009; 87: 1062-1068.
  • 25
    Fasola CG, Klintmalm GB. Hepatitis C and mycophenolate mofetil—a clarification. Liver Transpl 2002; 8: 411-412; author reply 412-413.
  • 26
    Kornberg A, Kupper B, Tannapfel A, Hommann M, Scheele J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005; 5: 107-115.
  • 27
    Bahra M, Neumann UI, Jacob D, Puhl G, Klupp J, Langrehr JM, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005; 5: 406-411.
  • 28
    Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, et al. Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc 1998; 30: 2232-2233.
  • 29
    Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002; 34: 1563-1564.
  • 30
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
  • 31
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-46.
  • 32
    Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011; 24: 461-468.
  • 33
    Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003; 9: 57-61.
  • 34
    Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77: 1092-1104.
  • 35
    Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998; 29: 29-35.
  • 36
    Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-714.
  • 37
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
  • 38
    Cornberg M, Hinrichsen H, Teuber G, Berg T, Naumann U, Falkenberg C, et al. Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol 2002; 37: 843-847.